All Blogs

Sep 25, 2019

Hypoparathyroidism is a rare endocrine condition marked by low-calcium and high-phosphate levels as compared to a normally lower or inappropriate level of normal Parathyroid hormone (PTH). Understanding of the Hypoparathyroidism epidemiological data become difficult, considering that the country-specific data i...

Sep 25, 2019

World Lung Day World Lung Day, September 25th, is an occasion for us all to unite and promote better lung health globally. It is the day for people to raise awareness who are affected by respiratory disease, come together for lung health action. #KeepLungsHealthy #LungDay

Sep 24, 2019

Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics.  This oft...

Sep 23, 2019

Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...

Sep 21, 2019

World Alzheimer’s Day World Alzheimer’s Day takes place on 21 September of every year. World Alzheimer's Day is a campaign to raise awareness and highlight issues faced by people those who are affected by dementia. The exact cause of Alzheimer's disease is not known, although several things are considered to ...

Sep 20, 2019

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Classified as a "monoclonal antibody", Gazyva is a CD20-directed cytolytic antibody. The drug...

Sep 19, 2019

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Sep 18, 2019

Recently the U.S. Food and Drug Administration has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. A 50 mg, twice daily oral pill, Ibsrela is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen...

Sep 17, 2019

AlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research & Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and...

Aug 08, 2024

More than a dozen companies have shifted their focus toward the development of HR-positive/HER2-negative breast cancer drugs. Some of them are Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc.,...